Communiqués Hikma Pharmaceuticals PLC

Actions

HIK

GB00B0LCW083

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:23 04/09/2026			Varia. 5j.	Varia. 1 janv.
1 593,00 ^GBX	-0,75%		-1,42%	+2,77%

25/08	Citigroup passe à l'achat sur Next, UBS relève Drax	AN
21/08	Hikma Pharmaceuticals : rentabilité supérieure aux attentes au S1 ; mais le titre nécessite des biosimilaires internes pour une revalorisation durable

Communiqués

11/08	Hikma Pharmaceuticals : advances climate progress with first solar energy agreement	PU
22/07	Inspired at Hikma: Purpose-driven leadership, developing talent and building for growth. Meet Kristy Ronco	PU
23/06	Behind Better Health: Hikma's People	PU
22/06	Hikma Pharmaceuticals : welcomes FDA approval of Guardant360® Liquid CDx	PU
15/06	Supreme Court Addresses Induced Infringement Claims In Hikma v. Amarin	AQ
05/06	Hikma comments on Supreme Court of the United States unanimous decision in favour of Hikma	AQ
05/06	Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patients worldwide	AQ
04/06	Hikma Pharmaceuticals : comments on Supreme Court of the United States’ unanimous decision in favour of	PU
04/06	Hikma Pharmaceuticals : puts access to medicines at the heart of its sustainability strategy, reaching 222 million patient...	PU
14/05	Inspired at Hikma: Career growth, leadership and social impact. Meet Zeena Murad	PU
08/05	Working at Hikma’s Zagreb R&D hub: meet Nera Marjanovic	PU
08/05	Hikma Pharmaceuticals : Why the world needs more companies like Hikma. By Said Darwazah, Chief Executive Officer	PU
05/05	Hikma Pharmaceuticals : and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) C...	PU
28/04	Hikma Pharmaceuticals : announces settlement agreement for VYNDAMAX® (tafamidis)	PU
23/04	Hikma Pharmaceuticals : Results of our 2026 AGM	PU
23/04	Hikma Pharmaceuticals : Special Business passed at AGM	PU
23/04	Hikma Pharmaceuticals : Trading update April 2026	PU
23/04	Hikma Pharmaceuticals : reiterates full year 2026 guidance following encouraging start to the year	PU
16/04	Putting patients first through quality: a Q&A with Tyson Ardo, Associate Vice President, Quality	PU
18/03	Hikma Pharmaceuticals : Investing in R&D to drive high-value pipeline delivery	PU
18/03	Hikma Pharmaceuticals : Investing in manufacturing excellence at Hikma	PU
18/03	Hikma Pharmaceuticals : Investing in MENA to expand access and drive growth	PU
18/03	Hikma Pharmaceuticals : Investing in strategic partnerships driving growth in the US and MENA	PU
11/03	Hikma Pharmaceuticals : launches authorised generic of Nucynta® ER (tapentadol) extended-release in the US	PU
11/03	Hikma Pharmaceuticals : R&D. Innovation in formulation development. Meet Hamza Qassim	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Hikma Pharmaceuticals : rentabilité supérieure aux attentes au S1 ; mais le titre nécessite des biosimilaires internes pour une revalorisation durable

Le 21 août 2026 à 17:06

Hikma poursuit sa baisse malgré Berenberg

Le 11 août 2026 à 11:38